Phase I/II Study of a CpG-Activated Whole Cell Vaccine Followed by Autologous "Immunotransplant" for Mantle Cell Lymphoma
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The primary endpoint of the trial is freedom from molecular residual disease (MRD) at the landmark of one-year post-transplant.
After the one-year mark, samples for MRD analysis will be collected every 6 months for 3 years or until disease progression.
Samples for MRD analysis are collected every 3 months until one-year post transplant.
United States: Institutional Review Board
|Stanford University Medical Center||Stanford, California 94305-5408|